Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)
Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)
Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous [...]
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressive
AdComm experts were split on whether to approve Amgen's Tavneos (avacopan) in 2021, however, this sentiment has not been reflected in physician uptake and perception of Tavneos which has been [...]
Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)
Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)
Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous [...]
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressive
AdComm experts were split on whether to approve Amgen's Tavneos (avacopan) in 2021, however, this sentiment has not been reflected in physician uptake and perception of Tavneos which has been [...]